Values First Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History

Values First Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $0 - $0	0 New	0 $0
Q3 2020 Nov 15, 2022	SELL	$255.65 - $303.1 $281,215 - $333,410	-1,100 Closed	0 $0
Q2 2020 Nov 15, 2022	SELL	$225.48 - $295.8 $90,642 - $118,911	-402 Reduced 26.76%	1,100 $319,000
Q1 2020 Jan 09, 2023	BUY	$199.77 - $247.81 $274,284 - $340,243	1,373 New	1,373 $327 Million
Q4 2019 Nov 15, 2022	BUY	$166.71 - $223.91 $250,398 - $336,312	1,502 New	1,502 $329,000

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Values First Advisors, Inc. with notifications on news.